NEWSWIRETODAY Press Release& Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: Biocad
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biocad Announces New Treatment for Oncological Diseases - New Russian medical preparation Leucostim significantly improves effectiveness and availability in modern treatment of oncological diseases - Leucostim.ru
Biocad Announces New Treatment for Oncological Diseases

 

NewswireToday - /newswire/ - Moscow, Russia, 2006/01/09 - New Russian medical preparation Leucostim significantly improves effectiveness and availability in modern treatment of oncological diseases - Leucostim.ru.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Russian biotech company Biocad has successfully completed a multicenter comparative clinical trial of the first domestic granulocyte colony stimulating factor Leucostim. This trial was performed in three leading Moscow cancer centers. Leucostim was used for the treatment of 80 cancer patients with neutropenia after cytotoxic chemotherapy. 100% efficacy of Leucostim was demonstrated; its effect was profound and stable.

Results of the trial have proved that Leucostim has an excellent safety profile and a remarkable efficacy. Therefore Leucostim can be recommended for clinical use for treatment and prophylaxis of chemotherapy-related neutropenia.
All research that resulted in development of Leucostim was performed by Russian scientists. ZAO Biocad manufactures Leucostim in its ultramodern facility in Moscow region according to GMP regulations.

The launch of Leucostim is expected in mid-2006. Availability of this generic drug will make the effective therapy of cancer more affordable, which is of special importance for pediatric oncology and hematology. Therefore, by introducing this product into the Russian market Biocad contributes to the initiatives of the President of Russian Federation who has recently stipulated in the “Health” National Program that availability of hi-tech medical help has to be a priority.

Introduction of the first domestic granulocyte colony stimulating factor Leucostim into the medical practice now depends on whether governmental regulatory bodies will keep to the usual drug approval schedule.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Biocad

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biocad Announces New Treatment for Oncological Diseases

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Biocad.ru 
+7 495 9926628
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biocad securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biocad / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

PharmaEssentia Selects Veeva Data Cloud to Support Launch of Novel Therapy for Rare, Chronic Blood Cancers
Transgene and NEC Announce Positive Preliminary Data from Phase I Studies of TG4050 - A Novel Individualized Neoantigen Cancer Vaccine
DSM Plans New Production Site for Bovaer® in Dalry, Scotland
Celltrion Pharm Selects TrackWise QMS for Scalability and Data Integrity
Ipsen Adds Another Program into its Pre-clinical R&D Oncology Pipeline through An Exclusive Worldwide Collaboration with Accent Therapeutics
Evaxion Biotech Lauded by Frost & Sullivan for Helping Develop Highly Targeted Therapies with its AI Immunology Platforms
Kyowa Hakko Acclaimed by Frost & Sullivan for its Non-GMO, Allergen-free, Immune Support Paraprobiotic Ingredient, IMMUSE™
DSM to Acquire First Choice Ingredients to Accelerate Growth in Food and Beverage
STEMCELL Technologies Launches Human Pluripotent Stem Cell Characterization and Banking Services in Partnership with WiCell
Biocon Selects TrackWise to Enable Enterprise Quality Management Across Global Biopharmaceutical Operations
STEMCELL Technologies and Hubrecht Organoid Technology to Partner on Non-Oncology Organoid Drug Screening Services
Ipsen and Exicure Enter into Exclusive Collaboration Targeting Rare Neurodegenerative Disorders
Ipsen Strengthens its Pre-clinical Oncology Pipeline with An Exclusive Worldwide-collaboration with BAKX Therapeutics, Inc. for BKX-001
Pharma and Biotech to Highly Invest in RNA Therapeutics to Expedite Research & Development across the Globe Finds Frost & Sullivan
Parexel Commended by Frost & Sullivan for Developing a Flexible and Agile Delivery Model to Improve Clinical Trial Outcome

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  RightITnow, Inc.





 
  ©2022 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are proudly NOT affiliated with USA TODAY (usatoday.com)